about
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemiaRecurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome.A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia.The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseThe B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemiaImputation reliability on DNA biallelic markers for drug metabolism studiesAberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia.Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosisDevelopmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemiaEfficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemiaTruncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic LeukemiaAssociation between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemiaFarnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.Imatinib mesylate for the treatment of chronic myeloid leukemia.Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemiaDeregulation of DUX4 and ERG in acute lymphoblastic leukemia.Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance.New targets for Ph+ leukaemia therapy.New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia.Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments.Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations.Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells.Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias.Genetic Basis of Acute Lymphoblastic Leukemia.Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia.Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
P50
Q27851487-1E4A7D7C-53D3-47E6-BB62-B441524BCC56Q28390558-35654440-4A1C-4B8D-8CA7-4A15F09C6AA7Q33409349-7D89FDD4-0ADE-4FDE-A189-EC4B4B652FF2Q33849578-225F54F6-D671-4911-A015-4570FEF734B5Q34032263-109CCF09-4B80-46E8-B239-9B78850D45ABQ34099472-40B856A7-A929-4BD0-891E-1FE156F3D36FQ34166538-54826B6A-E1BC-4115-A239-545088738DCBQ34308571-EABD10AA-7775-4DB4-BE06-E273BF891DBBQ34314927-EFE4CAF1-9A7A-4998-B6FC-50BE814E27A0Q34325815-5E6F91B9-886F-44D2-99D6-349C220F025EQ34358106-748ACD17-39ED-47C1-AAD2-BCBD86FE0A27Q34457136-4A15850F-9304-4F97-8B78-00C13F2B06C5Q34588839-FFC09F9D-33BA-418B-8A10-53F2C7370BA0Q34750545-51A09938-C5BB-4356-8F6F-FD6441680473Q35553341-5D36E570-0F8C-432E-834A-4CF58C9C05DEQ36070567-AA9DC456-C49A-453E-BCDD-94FF021D5CBCQ36255484-C2B17BD3-5ABE-43C9-BD39-9F98AF1280FFQ36571783-02FED4C7-AC71-409A-9562-F1195FFE6276Q36579071-1966C0AA-BF39-4A55-BE24-F8894A1E41FCQ36599984-12A190C1-6897-4AD4-92A3-F59F7F63B71DQ36926129-F4537325-E05F-405B-8373-A600CDDDD8ADQ37170339-3860909A-ECA8-4FFD-BCE9-EB91A2771138Q37183434-D3D95AF4-CE90-4BC9-B225-A20191E0ED80Q37292784-6B70A446-A59E-4599-8EA8-91E1DAA27DF2Q37408629-067DC133-D22B-41EC-A07D-14BE14A299FBQ37483972-D5A148BF-308B-4A64-9C0F-EEFC7EEF7DD2Q37586848-C9A3A050-71C2-4CC6-8557-5FF0D28B6F5EQ37644029-7D56EFE9-0219-4255-B727-9E98B086888AQ37810095-2D721AB7-D1D1-4999-A26D-86C7A93E17AFQ38005040-DCD0FB81-ED71-4124-A77F-6EEA8F601068Q38037648-EEA8172F-5AC8-4942-974D-77DB6DBDA9E3Q38286872-DD9CB7DB-213E-4A3A-AC10-75F87190B15DQ38289019-744F3A76-1F54-4C53-AE33-767DC3C36EC6Q38374992-3EB990B3-0224-432E-B4EA-E3B06174B8C8Q38756843-B2FED422-A314-4712-93F5-60FD2AAACD06Q38793389-3F0706CB-D49F-4E82-9368-248C8823A731Q38911196-ABED3A57-E6EF-4F9E-886A-905319477FCFQ39180500-AF07F6A6-5909-4C20-9B5C-00FAA64B798BQ39370931-08B7A961-0BFE-46BB-A9F9-7056BF910F79Q39516382-AD6DD112-5381-4A34-94D3-B857230EA98A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ilaria Iacobucci
@ast
Ilaria Iacobucci
@de
Ilaria Iacobucci
@en
Ilaria Iacobucci
@es
Ilaria Iacobucci
@fr
Ilaria Iacobucci
@it
Ilaria Iacobucci
@nl
type
label
Ilaria Iacobucci
@ast
Ilaria Iacobucci
@de
Ilaria Iacobucci
@en
Ilaria Iacobucci
@es
Ilaria Iacobucci
@fr
Ilaria Iacobucci
@it
Ilaria Iacobucci
@nl
prefLabel
Ilaria Iacobucci
@ast
Ilaria Iacobucci
@de
Ilaria Iacobucci
@en
Ilaria Iacobucci
@es
Ilaria Iacobucci
@fr
Ilaria Iacobucci
@it
Ilaria Iacobucci
@nl
P106
P1153
57196345711
P31
P496
0000-0001-6210-5607